☆ 4.4 Article

The role of circulating biomarkers in predicting the 30-day mortality of immune checkpoint inhibitors-related myocarditis: a retrospective cohort study

INTERNAL AND EMERGENCY MEDICINE (2023)

Related references

Note: Only part of the references are listed.

Article Cardiac & Cardiovascular Systems

The predictive value of high sensitivity troponin measurements in patients treated with immune checkpoint inhibitors

Barliz Waissengein et al.

Summary: This study aimed to evaluate the changes in high sensitivity-Troponin (hs-Tn) levels in cancer patients treated with pembrolizumab and found that abnormally elevated hs-TnI was a significant predictor for the development of major adverse cardiac events (MACE) and all-cause mortality.

CLINICAL RESEARCH IN CARDIOLOGY (2023)

Add to Collection

Review Medicine, General & Internal

Diagnosis and Treatment of Acute Myocarditis A Review

Enrico Ammirati et al.

Summary: Acutemyocarditis is a sudden inflammatory injury to the myocardium, affecting around 4 to 14 people per 100 000 annually with a mortality rate of about 1% to 7%. The most common causes include viruses, autoimmune disorders, drugs, and vaccines. Symptoms include chest pain, dyspnea, and syncope. Diagnosis can be made through symptoms, biomarkers, electrocardiographic changes, and imaging/biopsy. Treatment depends on the severity, clinical presentation, and etiology.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2023)

Add to Collection

Article Biotechnology & Applied Microbiology

The foundations of immune checkpoint blockade and the ipilimumab approval decennial

Alan J. Korman et al.

Summary: Cancer immunotherapy has significantly impacted patient survival in multiple high-incidence cancer indications over the past decade, mainly due to the success of immune checkpoint blockade (ICB) drugs. These drugs block specific pathways to attenuate T cell activation, prevent, or reverse, acquired peripheral tolerance, leading to their effectiveness.

NATURE REVIEWS DRUG DISCOVERY (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Skeletal Muscle Disorders: A Noncardiac Source of Cardiac Troponin T

Jeanne du Fay de Lavallaz et al.

Summary: This study aimed to confirm the cardiac specificity of cTnT in patients with various skeletal muscle disorders (SMDs). The results showed that elevations in cTnT concentrations in patients with active chronic SMDs are common and not attributable to cardiac disease, while this phenomenon was not observed for cTnI. The re-expression of cTnT in skeletal muscle may partially explain this.

CIRCULATION (2022)

Add to Collection

Article Oncology

Cancer treatment and survivorship statistics, 2022

Kimberly D. Miller et al.

Summary: The number of cancer survivors in the United States is increasing due to population growth, aging, and improved detection and treatment. The most prevalent cancers are prostate, skin melanoma, and colon and rectum for males, and breast, uterine corpus, and thyroid for females. Treatment disparities exist, with Black patients being less likely to be diagnosed with early-stage cancer and having lower surgical receipt rates.

CA-A CANCER JOURNAL FOR CLINICIANS (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Identification of Pathogenic Immune Cell Subsets Associated With Checkpoint Inhibitor-Induced Myocarditis

Han Zhu et al.

Summary: This study identified expanded cytotoxic CD8(+) Temra cells in the blood of patients with ICI myocarditis, which were clonally expanded and exhibited activated and cytotoxic phenotypes. These cells progressed into an exhausted phenotype after glucocorticoid treatment. The study also demonstrated the interaction between these expanded cells and innate immune cells, as well as the absence of key anti-inflammatory signals.

CIRCULATION (2022)

Add to Collection

Article Oncology

Biomarker Trends, Incidence, and Outcomes of Immune Checkpoint Inhibitor-Induced Myocarditis

Alexi Vasbinder et al.

Summary: This study aimed to determine the biomarker trends and their association with the incidence and outcomes of immune checkpoint inhibitor (ICI) myocarditis. The results showed that patients with ICI myocarditis had elevated levels of AST, ALT, and CPK. An increase in noncardiac biomarkers, especially CPK, during ICI treatment should prompt further evaluation for ICI myocarditis.

JACC: CARDIOONCOLOGY (2022)

Add to Collection

Article Pharmacology & Pharmacy

Intrinsic Differences in Immune Checkpoint Inhibitor-Induced Myocarditis: A Retrospective Analysis of Real World Data

Yanna Lei et al.

Summary: This study aimed to identify baseline characteristics that could differentiate mild from severe immune checkpoint inhibitor (ICI) myocarditis. The severity of myocarditis may be correlated with lactate dehydrogenase (LDH) and troponin levels. Patients who experienced multiple immune-related adverse events (irAEs) typically had higher levels of LDH and myoglobin. Corticosteroid therapy is critical for the treatment of myocarditis.

FRONTIERS IN PHARMACOLOGY (2022)

Add to Collection

Article Oncology

Coronary artery disease and revascularization associated with immune checkpoint blocker myocarditis: Report from an international registry

Joseph Nowatzke et al.

Summary: ICB-myocarditis may coexist with coronary artery disease (CAD) and revascularization may result in a poorer prognosis.

EUROPEAN JOURNAL OF CANCER (2022)

Add to Collection

Review Pharmacology & Pharmacy

Immune Checkpoint Inhibitor Cardiotoxicity: Understanding Basic Mechanisms and Clinical Characteristics and Finding a Cure

Sarah Waliany et al.

Summary: ICIs alter the immune system's response to cancerous tissues but can lead to varying degrees of autoimmunity, with cardiovascular complications such as myocarditis emerging as significant side effects. Understanding the mechanisms underlying these toxicities may help improve patient outcomes by reducing treatment-related morbidity.

ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 61, 2021 (2021)

Add to Collection

Article Oncology

Circulating leukocyte-platelet complexes as a predictive biomarker for the development of immune-related adverse events in advanced non-small cell lung cancer patients receiving anti-PD-(L)1 blocking agents

Carlos Zamora et al.

Summary: The study found that NSCLC patients had higher percentages of circulating leukocyte-platelet (PLT) complexes, and specific types of CD4 + PLT + and CD14 + PLT + complexes were associated with different types of irAEs, serving as predictive factors.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)

Add to Collection

Article Immunology

Epicardial adipose tissue, inflammatory biomarkers and COVID-19: Is there a possible relationship?

Alireza Abrishami et al.

Summary: This study aimed to evaluate the prognostic value of epicardial adipose tissue (EAT) in COVID-19 and its correlation with other inflammatory biomarkers. The results showed that EAT volume was positively correlated with inflammatory markers NLR and PLR, negatively correlated with LCR, and EAT density was significantly different between decedents and survivors.

INTERNATIONAL IMMUNOPHARMACOLOGY (2021)

Add to Collection

Article Oncology

Temporal Trends and Outcomes Among Patients Admitted for Immune-Related Adverse Events: A Single-Center Retrospective Cohort Study from 2011 to 2018

Gabriel E. Molina et al.

Summary: The study aimed to analyze severe immune-related adverse events seen among hospitalized patients receiving ICI therapy. The most common reasons for hospitalization were gastrointestinal, pulmonary, and hepatic toxicities. Patients with multiple organ involvement had a higher risk of inpatient mortality.

ONCOLOGIST (2021)

Add to Collection

Article Multidisciplinary Sciences

Association of blood biomarkers and autoimmunity with immune related adverse events in patients with cancer treated with immune checkpoint inhibitors

Despina Michailidou et al.

Summary: This study investigated the association between immune related adverse events (irAEs) and biomarkers in cancer patients receiving immune checkpoint inhibitors, identifying several risk factors. Patients with specific laboratory markers and clinical features had an increased risk of irAEs while lower NLR, MLR, and PLR were associated with longer overall survival. These findings suggest that baseline measurements and autoimmune history play a role in predicting irAEs and outcomes.

SCIENTIFIC REPORTS (2021)

Add to Collection

Article Oncology

Clinical characteristics, time course, treatment and outcomes of patients with immune checkpoint inhibitor-associated myocarditis

Igor Puzanov et al.

Summary: Monitoring troponin levels may predict mortality in cancer patients treated with ICI. Early detection of troponin elevation is associated with earlier intervention and improved outcomes in ICI-associated myocarditis. Recommended assessment and diagnostic studies guiding treatment decisions are presented.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Add to Collection

Article Oncology

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events

Julie R. Brahmer et al.

Summary: ICIs are standard treatments for cancer, but come with risks of immune-related adverse events. The SITC convened an expert panel to develop guidelines for managing irAEs, aiming to improve patient outcomes through evidence-based recommendations.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Add to Collection

Article Medicine, General & Internal

Optimized combination of circulating biomarkers as predictors of prognosis in AECOPD patients complicated with Heart Failure

Can Yao et al.

Summary: The study aimed to investigate the prognostic value of circulating biomarkers in predicting mortality of AECOPD patients with HF. High levels of NLR, CRP/ALB, and NT-proBNP may be clinically useful predictors for death in these patients. Combining NLR with CRP/ALB and NT-proBNP provides higher accuracy for predicting 28-day mortality.

INTERNATIONAL JOURNAL OF MEDICAL SCIENCES (2021)

Add to Collection

Article Pathology

Immune checkpoint inhibitor associated myocarditis occurs in both high-grade and low-grade forms

Samantha N. Champion et al.

MODERN PATHOLOGY (2020)

Add to Collection

Article Medical Laboratory Technology

Histopathologic Characterization of Myocarditis Associated With Immune Checkpoint Inhibitor Therapy

Irina Sobol et al.

ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2020)

Add to Collection

Review Oncology

Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy

Chongxian Pan et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)

Add to Collection

Letter Cardiac & Cardiovascular Systems

Major Adverse Cardiovascular Events and the Timing and Dose of Corticosteroids in Immune Checkpoint Inhibitor-Associated Myocarditis

Lili Zhang et al.

CIRCULATION (2020)

Add to Collection

Article Cardiac & Cardiovascular Systems

Decreased Absolute Lymphocyte Count and Increased Neutrophil/Lymphocyte Ratio With Immune Checkpoint Inhibitor-Associated Myocarditis

Zsofia D. Drobni et al.

JOURNAL OF THE AMERICAN HEART ASSOCIATION (2020)

Add to Collection

Review Oncology

Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance

Filipe Martins et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2019)

Add to Collection

Article Oncology

Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors

Alberto Pavana et al.

ONCOLOGIST (2019)

Add to Collection

Article Cardiac & Cardiovascular Systems

Myocarditis in the Setting of Cancer Therapeutics Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology

Marc P. Bonaca et al.

CIRCULATION (2019)

Add to Collection

Article Oncology

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

Julie R. Brahmer et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

Add to Collection

Article Cardiac & Cardiovascular Systems

Myocarditis in Patients Treated With Immune Checkpoint Inhibitors

Syed S. Mahmood et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)

Add to Collection

Letter Medicine, General & Internal

Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis

Javid J. Moslehi et al.

LANCET (2018)

Add to Collection

Article Oncology

Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced Non-Small Cell Lung Cancer Patients

Matteo Sarocchi et al.

ONCOLOGIST (2018)

Add to Collection

Article Oncology

Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer

Laura Mezquita et al.

JAMA ONCOLOGY (2018)

Add to Collection

Article Clinical Neurology

Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer

Mehdi Touat et al.

NEUROLOGY (2018)

Add to Collection

Article Oncology

Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study

Joe-Elie Salem et al.

LANCET ONCOLOGY (2018)

Add to Collection

Article Oncology

Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline

Saro H. Armenian et al.

JOURNAL OF CLINICAL ONCOLOGY (2017)

Add to Collection

Review Immunology

Myocarditis in auto-immune or auto-inflammatory diseases

Cloe Comarmond et al.

AUTOIMMUNITY REVIEWS (2017)

Add to Collection

Article Oncology

Prognostic relevance of lactate dehydrogenase in advanced pancreatic ductal adenocarcinoma patients

Yuanyuan Xiao et al.

BMC CANCER (2017)

Add to Collection

Article Medicine, General & Internal

Fulminant Myocarditis with Combination Immune Checkpoint Blockade

Douglas B. dbj Johnson et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Add to Collection

Article Multidisciplinary Sciences

Prognostic value of platelet to lymphocyte ratio in non-small cell lung cancer: a systematic review and meta-analysis

Hua Zhang et al.

SCIENTIFIC REPORTS (2016)

Add to Collection

Article Cardiac & Cardiovascular Systems

Clinical course and predictive value of liver function tests in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST trial

Andrew P. Ambrosy et al.

EUROPEAN JOURNAL OF HEART FAILURE (2012)

Add to Collection

Article Oncology

Lactate dehydrogenase, Gleason score and HER-2 overexpression are significant prognostic factors for M1b prostate cancer

Yoshiaki Yamada et al.

ONCOLOGY REPORTS (2011)

Add to Collection

Review Oncology

Why do cancers have high aerobic glycolysis?

RA Gatenby et al.

NATURE REVIEWS CANCER (2004)

Add to Collection

Article Oncology

Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis

MI Koukourakis et al.

BRITISH JOURNAL OF CANCER (2003)

Add to Collection

© Peeref 2019-2024. All rights reserved.